Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERO OTCMKTS:GPLB NYSEAMERICAN:PHGE OTCMKTS:SKVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.02-25.5%$0.03$0.02▼$26.99$817K0.21551,383 shs292,816 shsGPLBGreen Planet Bioengineering$0.02$0.02$0.01▼$0.02$342K3.0732,167 shsN/APHGEBiomX$0.68-9.3%$3.77$0.62▼$14.71$1.20M1.02441,876 shs340,238 shsSKVISkinvisible$0.20-19.2%$0.28$0.08▼$0.90$1.35M1.841,103 shs2,454 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics0.00%+5.94%-0.29%-30.10%-99.80%GPLBGreen Planet Bioengineering0.00%0.00%0.00%0.00%-84.45%PHGEBiomX0.00%-22.59%-78.43%-86.17%-92.90%SKVISkinvisible0.00%-16.67%+5.43%0.00%-40.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.02-25.5%$0.03$0.02▼$26.99$817K0.21551,383 shs292,816 shsGPLBGreen Planet Bioengineering$0.02$0.02$0.01▼$0.02$342K3.0732,167 shsN/APHGEBiomX$0.68-9.3%$3.77$0.62▼$14.71$1.20M1.02441,876 shs340,238 shsSKVISkinvisible$0.20-19.2%$0.28$0.08▼$0.90$1.35M1.841,103 shs2,454 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics0.00%+5.94%-0.29%-30.10%-99.80%GPLBGreen Planet Bioengineering0.00%0.00%0.00%0.00%-84.45%PHGEBiomX0.00%-22.59%-78.43%-86.17%-92.90%SKVISkinvisible0.00%-16.67%+5.43%0.00%-40.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEROCERo Therapeutics 1.67Reduce$45.00202,602.70% UpsideGPLBGreen Planet Bioengineering 0.00N/AN/AN/APHGEBiomX 2.00Hold$26.003,723.53% UpsideSKVISkinvisible 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GPLB, PHGE, SKVI, and CERO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/9/2026PHGEBiomX HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/A($12.50) per shareN/ASKVISkinvisible$20K54.54N/AN/A($1.90) per share-0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEROCERo Therapeutics-$8.30M-$102.61N/AN/AN/AN/AN/A-209.40%6/3/2026 (Estimated)GPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AN/AN/AN/APHGEBiomX-$36.20M-$3.21N/AN/AN/AN/A-2,923.50%-83.44%5/14/2026 (Estimated)SKVISkinvisible-$1.06M-$0.20N/AN/AN/A-5,315.00%N/A-767.34%N/ALatest GPLB, PHGE, SKVI, and CERO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2026Q4 2025SKVISkinvisibleN/A-$0.05N/A-$0.05N/AN/A2/19/2026Q4 2025PHGEBiomXN/A$6.99N/A$6.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCEROCERo TherapeuticsN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEROCERo TherapeuticsN/A0.560.56GPLBGreen Planet BioengineeringN/AN/AN/APHGEBiomXN/A0.870.87SKVISkinvisibleN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEROCERo Therapeutics29.64%GPLBGreen Planet BioengineeringN/APHGEBiomX40.57%SKVISkinvisibleN/AInsider OwnershipCompanyInsider OwnershipCEROCERo Therapeutics0.36%GPLBGreen Planet BioengineeringN/APHGEBiomX21.80%SKVISkinvisible53.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEROCERo Therapeutics836.79 million1.05 millionN/AGPLBGreen Planet Bioengineering120.01 millionN/ANot OptionablePHGEBiomX1201.59 million1.25 millionN/ASKVISkinvisible25.40 million2.54 millionNot OptionableGPLB, PHGE, SKVI, and CERO HeadlinesRecent News About These CompaniesSkinvisible Stock Price HistoryOctober 9, 2025 | investing.comOvation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments ...September 19, 2025 | theglobeandmail.comOvation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent ProtectionSeptember 18, 2025 | accessnewswire.comASkinvisible Delays 10-K Filing Due to Compilation IssuesMarch 31, 2025 | tipranks.comSkinvisible, Inc.: Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesJanuary 23, 2025 | finanznachrichten.deSkinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesJanuary 23, 2025 | accessnewswire.comASkinvisible, Inc. (SKVI)November 16, 2024 | finance.yahoo.comSkinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation DevelopmentOctober 3, 2024 | accesswire.comAPromising Data on Transdermal Obesity Formulations Announced by SkinvisibleJuly 11, 2024 | accesswire.comASkinvisible Expands Obesity Patent Application for Transdermal DeliveryJune 24, 2024 | accesswire.comASkinvisible, Inc.: Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finanznachrichten.deSkinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finance.yahoo.comZHUD Zhuding International LimitedMay 15, 2024 | seekingalpha.comSkinvisible, Inc.: Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | finanznachrichten.deSkinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | finance.yahoo.comSkinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | accesswire.comAFree weights 362X germier than a toilet seatMay 26, 2023 | mensjournal.comMSkinvisible, Inc. (SKVI) Stock Historical Prices & Data - Yahoo FinanceMarch 2, 2023 | finance.yahoo.comSKVI.PK - Skinvisible Inc | Stock Price & Latest News | ReutersSeptember 8, 2022 | reuters.comSkinvisible Inc: Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New DrugJune 6, 2022 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPLB, PHGE, SKVI, and CERO Company DescriptionsCERo Therapeutics NASDAQ:CERO$0.02 -0.01 (-25.50%) As of 03:57 PM EasternCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Green Planet Bioengineering OTCMKTS:GPLB$0.02 0.00 (0.00%) As of 05/1/2026Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.BiomX NYSEAMERICAN:PHGE$0.68 -0.07 (-9.33%) As of 04:10 PM EasternBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Skinvisible OTCMKTS:SKVI$0.20 -0.05 (-19.20%) As of 03:47 PM EasternSkinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
